Characterization of beta-lactamases in situ on polyacrylamide gels.
about
Patterns and mechanisms of beta-lactam resistance among isolates of Escherichia coli from hospitals in the United StatesCharacterization of CTX-M ESBLs in Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae clinical isolates from Cairo, Egypt.Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonaPlasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strainsbeta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United StatesDetection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center.Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillinUse of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.Low-virulence Citrobacter species encode resistance to multiple antimicrobials.Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogsNmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China.Extended-spectrum beta-lactamase enzymes in clinical isolates of Enterobacter species from Lagos, Nigeria.Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibioticsComparison of ampicillin-sulbactam regimens simulating 1.5- and 3.0-gram doses to humans in treatment of Escherichia coli bacteremia in mice.Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa.Modification of the double-disk test for detection of enterobacteriaceae producing extended-spectrum and AmpC beta-lactamases.Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.Ceftazidime resistance in Hafnia alveiRapid identification of metallo- and serine beta-lactamasesUse of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test.Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may findHigh-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, Ohio.Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.Community-onset disease caused by Citrobacter freundii producing a novel CTX-M beta-lactamase, CTX-M-30, in CanadaOccurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.
P2860
Q24676380-34DB2766-4065-4273-B3A4-06D278CE79A6Q33460720-00A9361E-6DB9-4B6C-AEE7-6F4AD3C0EF19Q33682354-06D752E0-CD5A-45C4-A894-D74BED7ADBB5Q33691113-1EE1E3BF-B4C2-4835-917B-59F9E7569FEFQ33693251-DC7BC12C-0D82-4117-B07D-F4C0030031D6Q33693985-76AB6E05-C23F-442C-B437-9BE70CF7ABCAQ33938126-166E3C46-4FE2-45EA-ACE4-594BE068FF5AQ33965292-B75920FC-49F6-4C07-8CA5-AEE18CA01A84Q33966850-4C09325C-E2DE-433B-AFC4-9E5DFE4205DDQ33976690-132E3DB0-E0EA-42F7-8E47-625B0166CD37Q33976916-85DAD6F4-9EE6-454E-893C-5F4878A73420Q33983667-5A3177E0-38D1-45E6-8FCD-FDFFFD6BA55BQ34142129-483771A5-20C5-414F-8EBB-BD1A4548FC25Q34252097-0A26DA75-CAF7-4471-86AA-A745F5F2BA89Q34488293-1048D78C-5603-4210-8987-DE59981C5CA3Q34821049-E07389B3-3715-4E85-B352-7EB48ACB1F6EQ34991503-F7904770-742E-48DC-8B84-F1DD980F8FB3Q35073335-EBBACDF6-0035-41F7-8FFF-B3E53C836BA2Q35111391-09E45BD1-940E-4CAF-AEE0-02C51DE7CF50Q35113629-FFA2C3FD-09EC-47DB-B2BC-201F921BDEFAQ35128789-2ED386FB-0CFD-4ABE-8DC5-2ECB8EB19A5EQ35130831-0DB903EA-4D44-4FE1-9EC3-422A996F4F34Q35134525-05028D5B-BA83-4D81-B0DB-C4324DA66F5EQ35252346-857D1624-9705-444E-8901-D1373841EDE6Q35343778-1ECE3DEA-F1B5-4FB3-B9CB-C1314D5BEFD5Q35563877-0DD78BAF-5519-4054-AA6F-02B43F484997Q35566058-97E32614-83BE-4FD5-9678-D338D4C315CEQ35638321-398E5EEE-B802-483D-A346-EB86641747EFQ35808603-464E3B01-E291-4E72-BA98-0B9319817067Q35816397-F274D662-16CC-4720-9E55-2CC5035E938EQ35820302-5C14224F-E6A2-4666-90D2-71FD16C70B64Q35826023-AA9D4585-ACB3-4F0B-8D12-37EE2E1B1ECFQ35843025-19290DAF-276D-400D-8397-EB51FFFCCD8DQ35904057-29EA808E-081D-4B8C-813A-61729F1A66DDQ36541997-5D92F181-4601-4432-9D46-7AC75188A0A3Q36546913-FEBD3E34-DA08-48CB-AF94-4EAE7F3031C9Q36753939-1E3B0A9B-5BBD-4CFE-992F-58BE6441DA33Q36932909-BCC34A4F-C27F-4A8B-9AAC-06DE5B992E9EQ37598697-43AFBA7B-9BDE-417C-9EF2-53D6E840CC0CQ38454462-70C63417-7436-42D4-B2F9-5374A985D891
P2860
Characterization of beta-lactamases in situ on polyacrylamide gels.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Characterization of beta-lactamases in situ on polyacrylamide gels.
@en
Characterization of beta-lactamases in situ on polyacrylamide gels.
@nl
type
label
Characterization of beta-lactamases in situ on polyacrylamide gels.
@en
Characterization of beta-lactamases in situ on polyacrylamide gels.
@nl
prefLabel
Characterization of beta-lactamases in situ on polyacrylamide gels.
@en
Characterization of beta-lactamases in situ on polyacrylamide gels.
@nl
P2093
P2860
P356
P1476
Characterization of beta-lactamases in situ on polyacrylamide gels.
@en
P2093
Sanders CC
Sanders WE Jr
P2860
P304
P356
10.1128/AAC.30.6.951
P407
P577
1986-12-01T00:00:00Z